Magnetic resonance imaging-guided daily adaptive prostate stereotactic radiation (MRg-A-SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques . But it is unknown whether this reduces side effects compared to standardly used computed tomography guided prostate cancer treatment . The pooled estimates for acute grade 2 or higher (G2+) genitourinary (GU) and gastrointestinal (GI) toxicity for MRg.Tyranies were 16% (95% confidence interval [CI], 10%–24%) and 4% . For CT, the risk of acute G2+ GU and GI toxicities was 28% and 9% CI, respectively . Longer follow-up will be needed to evaluate late toxicity and disease control outcomes .